Azacitidine/Venclexta improved EFS and quality of life compared to induction chemotherapy in fit AML patients, with a 39% risk reduction in disease progression or death. The PARADIGM trial showed a ...

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction chemotherapy in AML patients. The study highlighted reduced hospital stays, ...

Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase ...

Herein, we report the results of an open-label, single-center phase II clinical trial evaluating the efficacy of azacitidine in the setting of MRD-triggered (decrease of CD34 + donor chimerism below ...

Please provide your email address to receive an email when new articles are posted on . Azacitidine plus venetoclax significantly improved EFS compared with induction chemotherapy for certain patients ...

The goal of pharmaceutical intervention is to provide maximum therapeutic effectiveness with minimum risk to subjects. Orally administered medications allow for convenient dosing, but, because of ...

Learn everything you need to know about Azacitidine-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...